NCT01472926View on ClinicalTrials.gov

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis- (ATTEST)

PHASE2CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

December 10, 2013

Study Completion Date

December 10, 2013

Conditions
Stroke
Interventions
DRUG

Tenecteplase

Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)

DRUG

alteplase

Intravenous alteplase 0.9mg/kg to maximum of 90mg, given as 10% bolus and 90% of dose over 1 hour infusion

Trial Locations (1)

G51 4TF

Southern General Hospital, Glasgow

All Listed Sponsors
collaborator

University of Glasgow

OTHER

lead

NHS Greater Glasgow and Clyde

OTHER

NCT01472926 - Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis- (ATTEST) | Biotech Hunter | Biotech Hunter